EUVIMEDEUVIMED entdecken
Crossref

An acid-activatable fluorouracil prodrug for colorectal cancer synergistic therapy

Xiaoqian Ma, Nuo Lin, Ke Hu, Chao Xu, Qing Yang, Yushuo Feng, Peifei Liu, Haizhen Ding, Mengjiao Xu, Qianqian Shi, Hongmin Chen, Fangqin Xue

Acta Biomaterialia · 2024

DOI: 10.1016/j.actbio.2024.07.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2024. Verfasst von Xiaoqian Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, S…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Fluorouracil, Prodrugs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

5-Fluorouracil has demonstrated certain efficiency in patients with colorectal cancer. However, significant side effects of use by injection are common. To address this issue defects, a reengineered 5'-deoxy-5-fluorocytidine (DFCR) based drug delivery system (POACa) is developed as a prominent tumor-selective nano-activator. Investigations demonstrate that the constructed nano-activator exhibits good biocompatibility and high therapeutic efficiency in mice with subcutaneous and orthotopic SW-480 colorectal tumors, as its activity is strictly dependent on the tumor-associated acid environment and thymidine phosphorylase. These strategies diminish the off-target toxicity and improve the specificity and sensitivity of human colorectal cancer cells to 5-Fu, obtaining potent efficiency by the combination of H2O2 mediated oxidative stress, calcium overload and 5-Fu-induced chemotherapy (the combination index is 0.11). Overall, the engineered nano-activator exhibits a high therapeutic index in vitro and in vivo. STATEMENT OF SIGNIFICANCE: In this study, we designed and prepared a pH-responsive polymer to synchronously deliver DFCR (5'-deoxy-5-fluorocytidine, a prodrug of 5-Fu), Ca2+ and H2O2. The constructed nano-activator was denoted as POACa. (1) To address the problem of premature leakage of cargo by physical embedding, our research modified the inactive prodrug DFCR through chemical bonding. (2) The activation of the prepared nano-activator was strictly dependent on the tumor-associated acid environment and thymidine phosphorylase, providing the drug delivery system with inherent safety. (3) A distinctly low combination index value (0.11) of CaO2 and DFCR indicated that POACa has a prominent tumor suppression effect by tumor calcium overload sensitized chemotherapy and H2O2 mediated cytotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsFluorouracilProdrugsAnimalsHumansCell Line, TumorHydrogen PeroxideMiceMice, NudeMice, Inbred BALB CHydrogen-Ion ConcentrationDrug Synergism

Stichwörter der Autor:innen

5-FluorouracilCalciumChemotherapyColorectal cancerOxidative stress

Substanzen

FluorouracilProdrugsHydrogen Peroxide

Autor:innen und Institutionen

  • State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, China. State Key Laboratory…
  • Department of Gastrointestinal Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian Province, China. Clinical Medical Center for Digestive Diseases, Fujian P…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ma, X., Lin, N., Hu, K., Xu, C., Yang, Q., Feng, Y., Liu, P., Ding, H., Xu, M., Shi, Q., Chen, H., & Xue, F. (2024). An acid-activatable fluorouracil prodrug for colorectal cancer synergistic therapy. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2024.07.012

Vancouver

Ma X, Lin N, Hu K, Xu C, Yang Q, Feng Y, et al. An acid-activatable fluorouracil prodrug for colorectal cancer synergistic therapy. Acta Biomaterialia. 2024. doi:10.1016/j.actbio.2024.07.012

BibTeX
@article{Ma2024,
  author = {Ma, Xiaoqian and Lin, Nuo and Hu, Ke and Xu, Chao and Yang, Qing and Feng, Yushuo and Liu, Peifei and Ding, Haizhen and Xu, Mengjiao and Shi, Qianqian and Chen, Hongmin and Xue, Fangqin},
  title = {An acid-activatable fluorouracil prodrug for colorectal cancer synergistic therapy},
  journal = {Acta Biomaterialia},
  year = {2024},
  doi = {10.1016/j.actbio.2024.07.012}
}
Kostenlos starten →